Saiyun Bio Secures Tens of Millions in RMB in Series Angel+ Financing Led by CAS Star

VCBeat has learned that recently, a biotechnology company focused on the development of cutting-edge international delivery vector technologies and innovative drug therapiesSaiyun Biotechnology (Chengdu) Co., Ltd. (hereinafter referred to as “Saiyun Biotech”)Announced the completion of a tens-of-millions-level Angel+ round of financing. This round of financing was led by a well-known hard-tech investment institutionCASSTARExclusive investment; the funds raised will be primarily used to accelerate the development of the company’s self-developed pipeline.

Saiyun Biotechnology is a company dedicated to the research and development of targeted delivery technologies and innovative drug therapies. It has successfully developed a class of biomimetic delivery systems with independent intellectual property rights. Distinct from mainstream delivery carrier platforms, this rationally engineered system enables precise cellular delivery of various types of payloads, offering significant advantages in specific recognition, payload compatibility, protection, and production cost.

As an emerging type of delivery system, Saiyun Biotechnology’s R&D progress is currently at the international forefront. Previously, the company secured tens of millions of RMB in angel-round financing from well-known investment institutions, including Zhongfa Lingchuang/Life Science Park Venture Capital Fund, IDG Capital, and Inno Angel Investors. Incubated by the Life Science Park Venture Capital Shared Space, Saiyun Biotechnology has established a multi-technology platform R&D center in the Zhongguancun Life Science Park.

Saiyun Biotechnology boasts a team of seasoned scientists and industry experts, with multiple R&D pipelines established in fields such as targeted tumor therapy and cell and gene therapy. Currently, work on evaluating the efficacy and safety of related drug delivery systems, as well as optimizing manufacturing processes, is progressing in an orderly manner.

For this round of financing,Dr. Jiang Feng, Co-founder of Saiyun Biotechnologystated: “We extend our heartfelt gratitude to CASSTAR for its trust and support. In the field of precision medicine, drug delivery technology has long been a critical bottleneck constraining industry development. Currently, both small-molecule and macromolecular drugs face challenges related to low delivery efficiency, resulting in significant unmet clinical needs in this area. As an innovative enterprise focused on targeted delivery therapies for biological macromolecules, Saiyun Biotechnology leverages its independently developed novel drug delivery technology platform to explore frontier directions in drug delivery and is committed to driving breakthrough progress in the research and development of innovative drugs in China.”

CASSTARStatement: With the diversification of drug modalities, the value of delivery systems is becoming increasingly prominent. Hot emerging drug types such as cell and gene therapy (CGT), nucleic acids, antibody-drug conjugates (ADCs), and peptide drugs are all developed around the delivery of active pharmaceutical ingredients. Existing delivery systems still face unresolved challenges in areas such as specific cell targeting, endosomal escape, and payload variety, creating substantial industry demand for novel delivery systems. The research achievements of Professor Jiang Feng and Saiyun Biotechnology demonstrate significant innovative potential, with their core technology platform and R&D pipeline offering distinct advantages. This angel+ round investment in Saiyun Biotechnology is based on full recognition of its technical strength and market prospects. We believe that this investment will accelerate the translation of Saiyun Biotechnology’s technological achievements, bringing greater benefits to patients worldwide.

CASSTAR is an early-stage investment firm focused on the “hard tech” sector. As the originator of the “hard tech” concept and a pioneer in hard tech investing, CASSTAR is committed to building an integrated hard-tech entrepreneurship ecosystem that combines “research institutions + early-stage investment + startup platforms + post-investment services.” It provides professional, in-depth, and comprehensive investment, incubation, and financing solutions for technology entrepreneurs. Through long-term practice, CASSTAR has developed and proposed the ESK value investment framework, which integrates “Economic Value (E),” “Social Value (S),” and “Knowledge Value (K).” CASSTAR primarily invests in early-stage and start-up small and medium-sized technological enterprises with growth potential and independent innovation capabilities. The cumulative total size of its multiple funds exceeds RMB 12 billion.

In the biomedical sector, CASSTAR has actively invested in over 60 enterprises, covering biotechnology, innovative drugs, medical devices, and life science tools. It has cultivated leading companies in niche segments, including Micro-Light Medical, Shenxin Biology, Zehui Biotech, Bodong Medical, Tiangang Yinuo, SuperVision Imaging, Chaoshiji, and Yinming Biology. Looking ahead, CASSTAR will continue to increase its investments in biotechnology and innovative drugs, while expanding its footprint in biomanufacturing and the application of biotechnology across broader fields.